A detailed history of Altium Capital Management LP transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Altium Capital Management LP holds 385,000 shares of CPRX stock, worth $7.93 Million. This represents 2.7% of its overall portfolio holdings.

Number of Shares
385,000
Previous 500,000 23.0%
Holding current value
$7.93 Million
Previous $7.75 Million 1.19%
% of portfolio
2.7%
Previous 4.12%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$15.19 - $21.35 $1.75 Million - $2.46 Million
-115,000 Reduced 23.0%
385,000 $7.65 Million
Q1 2024

May 15, 2024

BUY
$13.18 - $17.11 $1.52 Million - $1.97 Million
115,000 Added 29.87%
500,000 $7.97 Million
Q4 2023

Feb 14, 2024

BUY
$11.78 - $17.29 $4.54 Million - $6.66 Million
385,000 New
385,000 $6.47 Million

Others Institutions Holding CPRX

About CATALYST PHARMACEUTICALS, INC.


  • Ticker CPRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 102,820,000
  • Market Cap $2.12B
  • Description
  • Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...
More about CPRX
Track This Portfolio

Track Altium Capital Management LP Portfolio

Follow Altium Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Altium Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Altium Capital Management LP with notifications on news.